FDA Emphasizes Confidentiality as Foundation of Public Trust, Innovation

FDA says its ability to uphold the “gold standard” of regulatory review depends as much on protecting confidential information as it does on scientific rigor. In a recent FDA Voices post, FDA chief operating officer Barclay Butler says the agency operates at a “unique crossroads” between transparency and confidentiality. While the public expects openness in decisions affecting health, he says, the integrity of their work relies on safeguarding sensitive data entrusted to it by companies, researchers, and consumers. “The FDA must maintain a delicate balance,” Butler said, “being a model of openness regarding the scientific basis of its decisions, while safeguarding the proprietary secrets of the industries it regulates.”

Federal laws such as the Trade Secrets Act and the Privacy Act require the agency to keep certain information confidential, even as the Freedom of Information Act (FOIA) promotes government transparency. Violating those confidentiality protections can lead to criminal liability, lawsuits, or disciplinary action, Butler notes.

According to Butler, FDA protects several key categories of information:

• Trade secrets, such as manufacturing processes and chemical formulas, which represent years of research and investment and drive continued innovation.
• Confidential commercial information, including financial data, market strategies, or customer lists that would cause harm if disclosed.
• Personal privacy information, such as the identities of patients or physicians who report safety concerns, to ensure public trust in reporting systems.
• Privileged internal documents, which allow staff scientists and experts to exchange unfiltered ideas and advice before decisions are finalized.
• Law enforcement records, such as inspection and investigation data, to protect ongoing probes and the confidentiality of sources.

The misuse or premature disclosure of any of this information could ripple through the economy, the agency warns. Because FDA decisions can affect stock prices and corporate performance, employees are barred from using nonpublic information for personal gain or sharing it with others — policies designed to prevent insider trading and preserve public confidence in financial markets.

FDA says it continues to release extensive data through FOIA and public databases, but must carefully review and redact information in categories that could cause harm if released. Each disclosure involves a line-by-line review to balance transparency with confidentiality.

Ultimately, Butler says, the agency’s protection of confidential information underpins the nation’s innovation ecosystem. Companies can submit their most sensitive data for regulatory review with confidence that it will remain secure. “By acting as a vigilant guardian of this information,” Butler concludes, “the FDA doesn’t just protect data — it protects the very cycle of innovation that brings new treatments to patients and keeps our food supply safe.”